SEC Form 4 · accession 0001209191-19-001912
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2019 | M | 2,800 | $5.5004 | A | 27,705 | D | |
| Common StockF2 | Jan 2, 2019 | S | 1,600 | $96.3496 | D | 26,105 | D | |
| Common StockF3 | Jan 2, 2019 | S | 1,200 | $97.0451 | D | 24,905 | D | |
| Common Stock | Jan 2, 2019 | M | 4,700 | $24.47 | A | 29,605 | D | |
| Common StockF4 | Jan 2, 2019 | S | 4,700 | $100.0881 | D | 24,905 | D | |
| Common Stock | Jan 3, 2019 | M | 100 | $24.47 | A | 25,005 | D | |
| Common Stock | Jan 3, 2019 | S | 100 | $100.32 | D | 24,905 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $5.5004 | Jan 2, 2019 | M | 2,800 | D | — | Jan 16, 2023 | Common Stock | 2,800 | 16,151 | D |
| Stock Option (right to buy)F6 | $24.47 | Jan 2, 2019 | M | 4,700 | D | — | Mar 3, 2024 | Common Stock | 4,700 | 9,300 | D |
| Stock Option (right to buy)F6 | $24.47 | Jan 3, 2019 | M | 100 | D | — | Mar 3, 2024 | Common Stock | 100 | 9,200 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 9, 2018.
- F2The range in prices for the transaction reported on this line was $95.90 to $96.86. The average weighted price was $96.3496. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range in prices for the transaction reported on this line was $96.90 to $97.60. The average weighted price was $97.0451. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The range in prices for the transaction reported on this line was $100.00 to $100.32. The average weighted price was $100.0881. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.
- F6This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.